ANDA 40710, held by Lannett Co Inc. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 40710 (Lidocaine Hydrochloride), held by Lannett Co Inc, was first approved by FDA on Feb 27, 2007, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine Hydrochloride Topical Solution USP, 4% is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 27, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride4% · solution;topical | Lidocaine Hydrochloride | Rx |
| Feb 21, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 27, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters